You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Nectin-4

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tumors Trial in Beijing ([68Ga]N188)

Recruiting
  • Neoplasms
  • Beijing, Beijing, China
    Peking University First Hospital
Jan 27, 2023

Solid Tumor Trial (18F-FDG)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Jul 18, 2022

Urothelial Carcinoma Trial in Beijing (18F-FDG)

Recruiting
  • Urothelial Carcinoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Jul 18, 2022

Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8 Trial in Phoenix,

Not yet recruiting
  • Metastatic Penile Squamous Cell Carcinoma
  • +3 more
  • Enfortumab Vedotin
  • Phoenix, Arizona
  • +2 more
Oct 23, 2023

Renal Pelvis and Ureter Urothelial Carcinoma Trial in Los Angeles (procedure, drug, biological)

Not yet recruiting
  • Renal Pelvis and Ureter Urothelial Carcinoma
  • Biopsy
  • +5 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Mar 15, 2023

18F-LN1 PET/CT in Urothelial Carcinomas

Recruiting
  • Urothelial Carcinoma
    • Chengdu, Sichuan, China
      Departments of Nuclear Medicine, Sichuan Provincial People's Hos
    Nov 2, 2023

    Early Onset Preeclampsia and Nectin-4

    Completed
    • Pre-Eclampsia
    • +3 more
    • serum marker levels
    • İstanbul, Turkey
      Hatice Akkaya
    Oct 16, 2021

    Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic

    Recruiting
    • Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation
    • +3 more
    • Cabozantinib S-malate
    • +3 more
    • Atlanta, Georgia
      Emory University Hospital/Winship Cancer Institute
    Aug 8, 2022

    Advanced Solid Tumors Trial in Guangzhou (BAT8007 for injection)

    Recruiting
    • Advanced Solid Tumors
    • BAT8007 for injection
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    May 26, 2023

    Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Tumor Trial in Atlanta (procedure,

    Not yet recruiting
    • Bladder Squamous Cell Carcinoma
    • +10 more
    • Biospecimen Collection
    • +5 more
    • Atlanta, Georgia
    • +3 more
    Feb 20, 2023

    Advanced Solid Tumor, Urinary Bladder Tumor, Pancreatic Tumors Trial in Worldwide (BT8009, Nivolumab)

    Recruiting
    • Advanced Solid Tumor
    • +4 more
    • Denver, Colorado
    • +20 more
    Nov 22, 2022

    Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter

    Recruiting
    • Locally Advanced Bladder Urothelial Carcinoma
    • +18 more
    • Los Angeles, California
    • +2 more
    Jun 28, 2022

    Urothelial Carcinoma, Triple Negative Breast Cancer, NSCLC Trial (SBT6290, pembrolizumab)

    Withdrawn
    • Urothelial Carcinoma
    • +4 more
    • (no location specified)
    Apr 4, 2022

    Nectin4-positive Advanced Malignant Solid Tumor Trial in Lishui, Wenzhou (CAR-T therapy for nectin4-positive malignant solid

    Unknown status
    • Nectin4-positive Advanced Malignant Solid Tumor
    • CAR-T therapy for nectin4-positive malignant solid tumor
    • Lishui, Zhejiang, China
    • +1 more
    Nov 16, 2020

    Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Testicular Germ Cell Tumors Trial run by the National

    Not yet recruiting
    • Adenocarcinoma of the Bladder
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Sep 22, 2023

    Pancreatic Ductal Adenocarcinoma, Pancreas Adenocarcinoma, Pancreas Cancer Trial in Kansas City (Enfortumab vedotin)

    Recruiting
    • Pancreatic Ductal Adenocarcinoma
    • +2 more
    • Enfortumab vedotin
    • Kansas City, Kansas
      University of Kansas Cancer Center
    Jun 23, 2023

    Solid Tumors Trial in United States (ADRX-0706)

    Recruiting
    • Solid Tumors
    • Los Angeles, California
    • +3 more
    Sep 12, 2023

    Advanced or Metastatic Solid Malignancies Trial in United States (Sitravatinib, Nivolumab, Pembrolizumab)

    Enrolling by invitation
    • Advanced or Metastatic Solid Malignancies
    • Beverly Hills, California
    • +12 more
    Aug 23, 2022

    Cancer, Tumor, Solid, Advanced Solid Tumor Trial in Houston (NTX-1088, Pembrolizumab)

    Recruiting
    • Cancer
    • +4 more
    • Houston, Texas
      The University of Texas MD Anderson Cancer Center
    Jan 24, 2023

    Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter Trial in United States (Sitravatinib, Nivolumab,

    Recruiting
    • Urothelial Carcinoma
    • +4 more
    • Tucson, Arizona
    • +33 more
    May 21, 2021

    Cancer, Advanced Solid Tumor Trial in Kettering (lorlatinib, encorafenib + binimetinib, talazoparib)

    Recruiting
    • Cancer
    • Advanced Solid Tumor
    • Kettering, Ohio
      Kettering Health Network
    Oct 14, 2022

    Carcinoma, Transitional Cell, Urinary Bladder Tumors, Urologic Tumors Trial in Worldwide (enfortumab vedotin (EV),

    Active, not recruiting
    • Carcinoma, Transitional Cell
    • +6 more
    • enfortumab vedotin (EV)
    • +4 more
    • Anchorage, Alaska
    • +105 more
    Dec 19, 2022

    Advanced Malignant Solid Tumor Trial in ShangHai (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)))

    Recruiting
    • Advanced Malignant Solid Tumor
    • Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
    • ShangHai, Shanghai, China
    • +1 more
    Apr 26, 2021

    Colorectal Cancer, Clostridioides Difficile Infection, Diarrhea Trial in Koscierzyna (Sanprobi IBS®)

    Recruiting
    • Colorectal Cancer
    • +2 more
    • Sanprobi IBS®
    • Kościerzyna, Poland
      Unit of Surgery with Unit of Oncological Surgery in Koscierzyna
    Aug 24, 2023

    Idiopathic Parkinson Disease Trial (MRx0029, MRx0005)

    Withdrawn
    • Idiopathic Parkinson Disease
    • MRx0029
    • MRx0005
    • (no location specified)
    Apr 19, 2023